We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$6.45B
AUM Growth
+$725M
Cap. Flow
-$581M
Cap. Flow %
-9%
Top 10 Hldgs %
18%
Holding
1,317
New
227
Increased
165
Reduced
129
Closed
313

Sector Composition

Rank Sector Weight
1 Financials 13.98%
2 Technology 9.11%
3 Energy 6.09%
4 Healthcare 4.57%
5 Utilities 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GNW icon
876
Genworth Financial
GNW
$3.85B
$104K ﹤0.01%
+20,752
New +$115K
ACTG icon
877
Acacia Research
ACTG
$447M
$103K ﹤0.01%
+26,623
New +$113K
SPIR icon
878
Spire Global
SPIR
$440M
$99.7K ﹤0.01%
18,654
FRXB.WS
879
DELISTED
Forest Road Acquisition Corp. II Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
FRXB.WS
$99.4K ﹤0.01%
10,000
SVRA icon
880
Savara
SVRA
$1.09B
$99K ﹤0.01%
+50,767
New +$114K
TNGX icon
881
Tango Therapeutics
TNGX
$4.34B
$98.8K ﹤0.01%
25,000
SKYX icon
882
SKYX Platforms
SKYX
$155M
$97.4K ﹤0.01%
+28,153
New +$92.7K
ANNX icon
883
Annexon
ANNX
$814M
$97K ﹤0.01%
+25,192
New +$139K
FRGI
884
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
$96.1K ﹤0.01%
+11,688
New +$97.1K
ATIP.WS
885
DELISTED
ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
ATIP.WS
$95K ﹤0.01%
373,720
FENC icon
886
Fennec Pharmaceuticals
FENC
$345M
$94.9K ﹤0.01%
+11,402
New +$106K
OMGA
887
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$94.7K ﹤0.01%
+15,706
New +$109K
LMDXW
888
DELISTED
LumiraDx Limited Warrant
LMDXW
$93.3K ﹤0.01%
200,600
RNAC icon
889
Cartesian Therapeutics
RNAC
$225M
$93.3K ﹤0.01%
+2,236
New +$105K
VATE icon
890
INNOVATE Corp
VATE
$106M
$90.8K ﹤0.01%
+3,058
New +$89.3K
LRMR icon
891
Larimar Therapeutics
LRMR
$398M
$90.3K ﹤0.01%
+19,944
New +$104K
CMRAW
892
DELISTED
Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027
CMRAW
$89.9K ﹤0.01%
100,000
KLTR icon
893
Kaltura
KLTR
$217M
$89.2K ﹤0.01%
+46,466
New +$91.3K
VRCA icon
894
Verrica Pharmaceuticals
VRCA
$92.8M
$86.1K ﹤0.01%
+1,324
New +$80.1K
PPTA
895
Perpetua Resources
PPTA
$2.18B
$82.8K ﹤0.01%
+18,607
New +$64.4K
GRNT icon
896
Granite Ridge Resources
GRNT
$601M
$81.2K ﹤0.01%
+13,834
New +$93.5K
CRBU icon
897
Caribou Biosciences
CRBU
$148M
$80.7K ﹤0.01%
15,207
CDZI icon
898
Cadiz
CDZI
$259M
$76.7K ﹤0.01%
+18,986
New +$76.6K
PSNYW icon
899
Polestar Automotive Holding ADS Class C-1
PSNYW
$343M
$75.8K ﹤0.01%
667
OCEA
900
DELISTED
Ocean Biomedical, Inc. Common Stock
OCEA
$71.9K ﹤0.01%
+10,830
New +$91.5K

Similar funds

LMR Partners's Q1 2023 Portfolio in Review

As of Q1 2023, LMR Partners held 1,317 positions worth $6.45B, up 13% from $5.73B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

LMR Partners withdrew a net $581M in Q1 2023, closing 313 positions and reducing 129 holdings. Its most notable exit was Bank of New York Mellon, an estimated $60M position sold in full.

By sector, the portfolio is most concentrated in Financials at 14% of assets, down from 15% a quarter earlier, followed by Technology and Energy.

Against the trend, LMR Partners opened a new position in AstraZeneca worth $42.7M.

  • LMR Partners's largest Q1 2023 buy was AstraZeneca: 307,414 shares worth $42.7M.
  • LMR Partners added most to First Horizon in Q1 2023, an estimated $77.4M increase.
  • LMR Partners's biggest Q1 2023 reduction was TSMC, cutting an estimated $121M.
  • LMR Partners fully exited Bank of New York Mellon in Q1 2023, selling an estimated $60M.
  • LMR Partners's ten largest holdings make up 18% of its $6.45B portfolio in Q1 2023.
  • LMR Partners opened 227 new positions and closed 313 in Q1 2023.
  • LMR Partners's portfolio value rose 13% quarter-over-quarter to $6.45B.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.